Compare ESP & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | ADAG |
|---|---|---|
| Founded | 1928 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.4M | 254.4M |
| IPO Year | 1995 | 2020 |
| Metric | ESP | ADAG |
|---|---|---|
| Price | $69.80 | $3.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $64.00 | $8.25 |
| AVG Volume (30 Days) | 16.6K | ★ 366.1K |
| Earning Date | 05-13-2026 | 04-01-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | ★ 31.88 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $43,950,872.00 | N/A |
| Revenue This Year | $10.30 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | $40.25 | ★ N/A |
| Revenue Growth | ★ 13.46 | N/A |
| 52 Week Low | $30.26 | $1.44 |
| 52 Week High | $73.50 | $4.75 |
| Indicator | ESP | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 64.67 | 47.08 |
| Support Level | $42.46 | $3.49 |
| Resistance Level | $73.50 | $4.10 |
| Average True Range (ATR) | 3.22 | 0.23 |
| MACD | 0.14 | -0.06 |
| Stochastic Oscillator | 79.54 | 47.09 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.